Focus on Investigational Drugs to Treat Heart Failure

We have been focusing on Cancer with our last updates focused on Breast Cancer and Lung Cancer.

We take a moment now to focus on the number one cause of death in the US, Heart Disease.

There are eleven investigational drugs for Heart failure in the Pharmaceutical Pipeline Tracker. Of the 23 investigational drugs with PDUFA dates, none are targeting Heart Failure. However, three investigational drugs to treat Heart failure have FDA Priority Designations.

​Vericel’s ixmyelocel-T is a fully closed cell-processing system that expands mesenchymal stromal cells and macrophages, which create anti-inflammatory and pro-angiogenic factors to repair damaged tissue and is administered via transendocardial injection.  Ixmyelocel-T has orphan drug status for dilated cardiomyopathy and Fast Track status for peripheral ischemia.  It has also received a Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA along with a Rare Pediatric Disease designation. There are links to two published studies for Ixmyelocel-T in the Pharmaceutical Pipeline Tracker.

Mesoblast’s MPC-150-IM is a mesenchymal precursor cell therapy that is administered via Intravenous Infusion in Phase III trials. MPC-150-IM is competing with Biocardia's autologous mesenchymal stem cell product. Mesoblast has the ongoing 600 patient, Phase III, DREAM HF-1 trial evaluating whether MPC-150-IM can reduce nonfatal heart failure-related major adverse cardiac events in moderate heart failure patients. The FDA has given MPC-150-IM a Rare Pediatric Disease and Regenerative Medicine Advanced Therapy (RMAT) priority designations. There is one published study for MPC-150-IM in the Pharmaceutical Pipeline Tracker.

Ironwood Pharmaceuticals’ praliciguat is an oral soluble guanylate cyclase (sGC) stimulator that improves nitric oxide (NO) signaling, which is being developed for heart failure with preserved ejection fraction (HFpEF) and diabetic nephropathy. The drug is in an on-going Phase II Trial and has a Fast Track priority designation from the FDA.

Subscribe to the Pharmaceutical Pipeline Tracker to review investigational drugs focused on Heart Failure. Read about safety, efficacy and the latest news. Take a look at published research links.